Interim Analysis of Phase II PURE-01 Trial: Neoadjuvant Pembrolizumab in Patients With Muscle-Invasive Urothelial Bladder Carcinoma

June 1-5, 2018; Chicago, Illinois
Neoadjuvant pembrolizumab associated with a pathologic CR rate of 39.5% and no surgical delay in MIBC patients scheduled for radical cystectomy.
Format: Microsoft PowerPoint (.ppt)
File Size: 189 KB
Released: June 12, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on immunotherapy for HCC and BTCs

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 18, 2021

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on CAR T-cell therapy

person default Caron A. Jacobson, MD Jae H. Park, MD Noopur Raje, MD Released: June 18, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for advanced HCC

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 17, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the optimal use of immune checkpoint inhibitors for early HCC and advanced BTC

Lipika Goyal, MD R. Kate Kelley, MD Amit G. Singal, MD, MS Released: June 17, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue